Pacira Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Pacira BioSciences achieved profitability in 2025 with increased product revenues, new strategic partnerships, and significant pipeline advancements, despite legal challenges and an IPR&D impairment.
NASDAQ
10-K: Pacira BioSciences Navigates Patent Challenges, Focuses on Growth Strategy in 2024 10-K Filing
Pacira BioSciences reports on its 2024 financial performance, strategic initiatives, and ongoing legal and regulatory landscape, highlighting both challenges and opportunities for growth in the non-opioid pain management market.
NASDAQ
Pacira BioSciences' 2023 10-K filing highlights its commitment to non-opioid pain management, strategic initiatives for growth, and financial performance.